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Abstract: Testing for mutations in the KRAS oncogene for patients with metastatic colorectal cancer (mCRC) is generally performed 
using DNA from formalin-fixed paraffin-embedded tumor tissue; however, access to specimens can be limited and analysis   challenging. 
This study assessed the identification of KRAS mutations in circulating free DNA (cfDNA) using a commercially available KRAS 
polymerase chain reaction (PCR) kit. Matched plasma, serum and tumor samples were available from 71 patients with mCRC who 
had received prior therapy but whose disease progressed following therapy. Yields of cfDNA from plasma and serum samples were 
  comparable. Analyses were successful in 70/71 plasma-extracted samples (specificity: 97%, sensitivity: 31%) and 67/71 serum-  extracted 
samples (specificity: 100%, sensitivity: 25%). This study demonstrates that KRAS mutations can be detected in cfDNA using a com-
mercially available KRAS PCR kit, confirming cfDNA as a potential alternative source of tumor DNA in a diagnostic setting if access 
to archival tumor specimens is limited.
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Introduction
The  human  oncogene  KRAS  encodes  a  G-protein 
responsible for signal transduction from the epidermal 
growth factor receptor (EGFR) and other cell-surface 
proteins to various intracellular targets.1,2   Activating 
mutations  in  KRAS  are  observed  in  30%–40%  of 
human colorectal tumors2,3 and are a predictor of poor 
outcomes in patients with metastatic colorectal cancer 
(mCRC) who receive treatment with anti-EGFR anti-
bodies alone or in combination with chemotherapy.4–9 
Thus  patients  with  mCRC  are  routinely  tested  for 
KRAS mutation before they receive anti-EGFR anti-
body therapy and only patients with wild-type KRAS 
should receive such therapy.10,11
Currently, KRAS mutations are usually assessed in 
DNA isolated from formalin-fixed, paraffin-  embedded 
(FFPE) biopsy or resection samples.12 The isolation 
of sufficient DNA of adequate quality for biomarker 
analysis from such FFPE samples is, however, not 
always possible. The amount of tumor DNA available 
is  often  limited.13  Moreover,  chemical  degradation 
of DNA can occur in FFPE samples13,14 and delayed 
fixation and cold ischemia can affect the integrity of 
DNA samples between removal from the patient and 
preservation,  rendering  the  quality  of  the  samples 
unsuitable for biomarker analyses.15
An alternative method to assess KRAS mutation 
is the analysis of tumor-derived, cell-free or circu-
lating  free  DNA  (cfDNA).  Tumor-derived  cfDNA 
can be extracted from plasma or serum and has the 
potential to be a viable starting material for the iden-
tification of genetic markers for diagnosis and recur-
rence of CRC, and for the early detection of disease 
recurrence.16–18  The  use  of  tumor-derived  cfDNA 
also offers a number of potential benefits, including 
the fact that it is a much less invasive technique for 
mutation detection in comparison with acquisition of 
FFPE tumor   samples. In addition, analysis of cfDNA 
provides a real-time assessment of KRAS mutation 
status.    Moreover,  cfDNA  analysis  may  also  pro-
vide better representation of the disease as a whole, 
as it has the potential to yield information about all 
subclones of a tumor and could contain DNA frag-
ments from distant metastatic sites.17,19 However, it 
is important to be aware that analysis of cfDNA may 
not be suitable for assessment of whether patients 
have wild-type KRAS, since there is a risk of false 
negative results.
Previous studies have confirmed that cfDNA can 
be used for the detection of KRAS mutations in CRC.17 
However, mutant DNA represents only a small frac-
tion  of  total  cfDNA,16  and  therefore  is  often  not 
assessable using commercially available polymerase 
chain reaction (PCR) kits. In this study we assessed 
whether the QIAGEN® therascreen KRAS PCR kit 
could  be  modified  to  enhance  sensitivity,  without 
affecting specificity, in the detection of KRAS muta-
tions in cfDNA.
Materials and Methods
Samples
Tumor, plasma, and serum samples for this exploratory 
biomarker analysis were collected from a cohort of 
71 patients as part of a Phase II, randomized, double-
blind trial in patients with mCRC that progressed dur-
ing or after first-line therapy (NCT00278889). Archival 
diagnostic tumor tissue was collected via biopsy or 
resection in routine clinical practice, formalin fixed, 
stored at ambient temperature in pathology laborato-
ries and submitted as pre-study treatment specimens 
in the course of the Phase II trial. Thus the submitted 
tumor samples ranged in age from a few months to 
11 years prior to the start of this study. DNA was sub-
sequently extracted from the tumor samples approxi-
mately 3 years after study initiation. Plasma and serum 
samples (1 mL) were collected at the start of this study 
and were stored at −80 °C for approximately 5 years 
before cfDNA extraction. For both sample types DNA 
was analyzed immediately after extraction. The study 
was performed in accordance with the Declaration of 
Helsinki and was approved by the Institutional Review 
Boards of the participating centers, including approval 
for the retrospective analysis of collected samples. All 
patients provided written, informed consent for provi-
sion of plasma, serum, and tumor material.
role of funding source
This study was funded by AstraZeneca who designed 
the study and were involved in the collection, analy-
sis, and interpretation of data. The authors (including 
AstraZeneca employees and Laboratory Corporation 
of America®  employees)  were  responsible  for  the 
writing of the manuscript (with medical writing sup-
port as detailed in the acknowledgments section) and 
the decision to publish and to which journal it should 
be submitted.Circulating free DNA for KRAS mutation assessment
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DNA extraction and KRAS mutation 
analysis
DNA was extracted from FFPE tumor samples using 
the QIAGEN® QIAamp® DNA FFPE tissue kit accord-
ing to the manufacturer’s instructions.20 cfDNA was 
extracted from the plasma and serum samples using 
the QIAGEN® QIAamp® circulating nucleic acid kit 
according to the manufacturer’s instructions.21
KRAS  mutations  in  the  FFPE-tumor  extracted 
DNA  and  in  the  cfDNA  were  detected  using  the 
  QIAGEN® therascreen KRAS PCR kit via ARMS™ 
and  Scorpions™  probes.22  This  kit  utilizes  the 
  Scorpions™ technology, which determines the num-
ber of PCR cycles necessary to detect a fluorescent 
signal above the background signal (‘threshold cycle’ 
[Ct]) as an indicator of the target molecules present in 
the original sample. The kit includes a control assay 
(used to assess the total amount of input DNA) and 
mutation specific or “test” assays. The ∆Ct   values 
can  then  be  calculated  as  the  difference  between 
test and control assay Cts. According to the manu-
facturer,   approximately 1% sensitivity is achievable 
if control Cts are .24 and ,29.22 The QIAGEN® 
therascreen KRAS PCR kit enables the detection of 
seven KRAS mutations (G12A, G12R, G12D, G12C, 
G12S, G12V, and G13D; NCBI reference sequence: 
NM_004985),22 which were all assessed in the FFPE 
tumor DNA samples.
Serum-  and  plasma-extracted  cfDNA  samples 
were initially assessed in singleton; positive results 
were subsequently repeated in triplicate in order to 
verify their mutation status. Samples were classified 
as ‘mutation positive’ (M+) if they generated a posi-
tive result in at least one of the repeat analyses. Data 
were  analyzed  using  a  standard  analysis  criterion 
(‘M+ Confidence Level 1’), based on the recommen-
dations for the QIAGEN® therascreen KRAS PCR kit 
for FFPE tumor samples (ie, 1% ∆Ct values applied 
and diagnostic Ct data analyzed using #40 cycles of 
PCR),22 and three exploratory analysis criteria (M+ 
Confidence Levels 2, 3, and 4) (Table 1).
Statistical analyses
Five test characteristics were used to assess the per-
formance of the KRAS PCR kit in plasma- or serum-
extracted cfDNA, relative to its performance in FFPE 
tumor-extracted DNA, the current ‘gold standard’ for 
assessing KRAS mutation status in mCRC.
1. Sensitivity: the proportion of M+ samples identi-
fied from tumor-extracted DNA that were classi-
fied as M+ in plasma- or serum-extracted cfDNA.
2. Specificity:  the  proportion  of  mutation  negative 
(M−)  samples  identified  from  tumor-extracted 
DNA  that  were  classified  as  M−  in  plasma-  or 
serum-extracted cfDNA.
3. Positive  predictive  value  (PPV):  the  proportion 
of samples classified as M+ in plasma- or serum-
extracted cfDNA that were identified to be M+ in 
tumor-extracted DNA (true positives).
4. Negative predictive value (NPV): the proportion 
of samples classified as M− in plasma- or serum-
extracted cfDNA that were identified to be M− in 
tumor-extracted DNA (true negatives).
5. Tumor versus cfDNA concordance: the proportion 
of total true positive and true negative results out 
of all samples tested.
Results
FFPe tumor-extracted DNA
FFPE tumor samples for KRAS mutation analysis were 
available from 109 patients with mCRC. Overall, 108 
(99.1%) of the FFPE samples were analyzed success-
fully; 48 of these (44%) were found to be KRAS M+. 
This  mutation  frequency  is  similar  to  that  seen  in 
other  studies.2,3  Of  the  seven  mutations  in  codons 
Table 1. Standard and exploratory analysis criteria (M+ Confidence Levels 1–4).
reduction in assay  
stringency
1.  Positive according to kit guidelines 
2.  Close to ∆Ct cut-off, diagnostic Ct . 40 cycles 
3.  2–3 Cts outside of cut-off, diagnostic Ct . 40 cycles 
4.   Any other putative positive result (has to show exponential 
amplification)
Increasing confidence   
in results
   
Abbreviations: Ct, threshold cycle; M+, mutation positive.Morgan et al
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12 and 13 of KRAS that the kit could detect (G12A, 
G12R, G12D, G12C, G12S, G12V, and G13D; NCBI 
reference sequence: NM-004985) all but the G12R 
mutation were detected (Fig. 1).
Adaptation of the QIAGeN® therascreen 
KrAS PCr kit for use with cfDNA
When the QIAGEN® therascreen KRAS PCR kit was 
used to analyze extracted cfDNA, the mean control Ct 
was 31−32. According to the manufacturer’s guidance 
∆Ct values for the seven KRAS mutations should range 
from 6.5 to 9 for 1% mutant samples. This suggests 
that mutations present at low levels might be missed 
if the assay was run for the recommended 40 cycles. 
Therefore, the assay was run for 50 cycles of PCR to 
improve  the  likelihood  of  detecting   mutations.  Due 
to the limited amount of sample,   plasma- and serum-
  extracted cfDNA were not analyzed for the G12R muta-
tion, which was not detected in any FFPE samples.
Utility of cfDNA for KRAS mutation 
analysis
Plasma- and serum-extracted cfDNA yields
Matched plasma and serum samples were available 
from 71 patients with analyzed FFPE tumor samples; 
for the remaining 38 patients the amount of plasma 
and  serum  available  was  insufficient  for  cfDNA 
extraction. Control Ct values for plasma- and serum-
extracted cfDNA samples, which are indicative of the 
total DNA yields, were similar (mean: 31.93 and 31.35; 
range 24 to 35 and 28 to 35, respectively;   Figure 2). 
Mutations of KRAS continued to be detected when 
control Ct values were high, suggesting that muta-
tions can still be detected even when the overall DNA 
yield is low (Fig. 2). Average ∆Ct values were lower 
in plasma samples than serum samples, suggesting 
that the mutation load in plasma was higher (Fig. 2).
Plasma-extracted cfDNA versus  
tumor-extracted DNA
KRAS  mutation  analysis  was  successful  in  70/71 
(98.6%) of the plasma-extracted cfDNA samples. At 
M+ Confidence Level 1, eight of the samples were 
positive, all of which were also M+ in the tumor 
(Table 2). One additional positive plasma sample 
(negative in the tumor) was identified when the M+ 
Confidence Level was increased from Level 1 to 2. 
Detailed analysis of this sample suggested that this 
was likely to be a true positive result even though 
no  mutation  was  detected  in  the  matched  tumor: 
∆Ct   values were reproducible in four replicates and 
PCR plots showed exponential amplification (data 
not  shown).  In  addition,  there  was  no  evidence 
of non-specific amplification at or near to the rel-
evant cycle number in any other samples. At M+ 
Confidence Level 3, two further positive samples 
were detected (both of which were positive in the 
tumor). A false positive (tumor negative) result was 
detected when the M+ Confidence Level 4 analysis 
criterion was used and no further positive results 
were  observed  where  the  tumor  had  generated  a 
positive result.
In  summary,  applying  less  stringent  analy-
sis    criteria  resulted  in  increased  assay  sensitivity. 
  However,  decreased  assay  specificity  for  plasma-
  extracted cfDNA was observed if the analysis criteria 
were adjusted too far (Table 2). These data suggest 
that M+ Confidence Levels 1–3 would be appropriate 
analysis criteria for detection of KRAS mutations in 
plasma-extracted cfDNA samples.
Serum-extracted cfDNA versus  
tumor-extracted DNA
Overall,  67/71  (94.4%)  of  the  serum-extracted 
cfDNA samples were analyzed successfully. Assay 
  sensitivity for serum-extracted cfDNA increased as 
the stringency of the analysis criteria was reduced 
(Table  3).  This  effect  was  particularly  marked 
when the M+ Confidence Level was increased from 
Level 1 to 2; in this instance, an extra three positive 
samples were detected, all of which were also M+ in 
the tumor (Table 3). One additional positive sample 
GLY12ALA
GLY12ARG ( not detected)
GLY12ASP 
GLY12CYS 
GLY12SER 
GLY12VAL 
GLY13ASP 
Figure 1. Frequency of specific KRAS mutations in FFPe tumor   samples. 
The PCr kit used in the analysis could detect seven mutations in codons 
12 and 13 of KRAS. 
note: Samples from 109 patients were analyzed; data are shown for the 
48 M+ samples.Circulating free DNA for KRAS mutation assessment
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Figure 2. Mutation threshold cycle (Ct) values in plasma- and serum-extracted cfDNA samples.
Table  2.  Comparison  of  KRAS  mutation  prevalence 
between  plasma-extracted  cfDNA  and  tumor-extracted 
DNA samples using four different analysis criteria.
plasma (n = 70) KRAS tumor type (n = 71)
positive not detected
Confidence Level 1
Test outcome
  Positive
  Unknown
 
8
24
 
0
39
Sensitivity: 0.25 Specificity: 1
PPV: 1 NPV: 0.62
Confidence Levels 1 and 2
Test outcome
  Positive
  Unknown
 
8
24
 
1
38
Sensitivity: 0.25 Specificity: 0.97
PPV: 0.89 NPV: 0.61
Confidence Levels 1, 2, and 3
Test outcome
  Positive
  Unknown
 
10 
22
 
1 
38
Sensitivity: 0.31 Specificity: 0.97
PPV: 0.91 NPV: 0.63
Confidence Levels 1, 2, 3, and 4
Test outcome
  Positive
  Unknown
 
10 
22
 
2 
37
Sensitivity: 0.31 Specificity: 0.95
PPV: 0.83 NPV: 0.63
was  observed  when  the  stringency  of  the    analysis 
  criteria  was  reduced  to  M+  Confidence  Level  4 
(Table 3). However, in order to avoid false positives 
and in line with the plasma sample data, we judged 
that M+ Confidence Levels 1–3 would be appropriate 
analysis criteria for the detection of KRAS mutations 
in serum-extracted cfDNA samples.
Table  3.  Comparison  of  KRAS  mutation  prevalence 
between  serum-extracted  cfDNA  and  tumor-extracted 
DNA samples using four different analysis criteria.
serum (n = 67) KRAS tumor type (n = 71)
positive not detected
Confidence Level 1
Test outcome
  Positive 
  Unknown
 
5 
27
 
0 
39
Sensitivity: 0.16 Specificity: 1
PPV: 1 NPV: 0.59
Confidence Levels 1 and 2
Test outcome
  Positive 
  Unknown
 
8 
24
 
0 
39
Sensitivity: 0.25 Specificity: 1
PPV: 1 NPV: 0.62
Confidence Levels 1, 2, and 3
Test outcome
  Positive 
  Unknown
 
8 
24
 
0 
39
Sensitivity: 0.25 Specificity: 1
PPV: 1 NPV: 0.62
Confidence Levels 1, 2, 3, and 4
Test outcome
  Positive 
  Unknown
 
9 
23
 
0 
39
Sensitivity: 0.28 Specificity: 1
PPV: 1 NPV: 0.63
Singleton analyses
Serum- and plasma-extracted cfDNA samples were 
initially assessed in singleton; positive results were 
subsequently repeated in triplicate in order to verify 
their mutation status. The results from the initial sin-
gleton analyses showed that, for both sample types, 
sensitivity increased but specificity decreased when Morgan et al
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Table 4. Assay sensitivity and specificity in plasma- and 
serum-extracted cfDNA samples using different analysis 
criteria (singleton analysis).
M+ Confidence Level
1 1 and 2 1, 2, and 3 1, 2, 3, and 4
Plasma
  Sensitivity 0.25 0.28 0.34 0.38
  Specificity 1 0.90 0.90 0.85
Serum
  Sensitivity 0.19 0.25 0.28 0.34
  Specificity 1 0.97 0.97 0.97
Abbreviation: M+, mutation positive.
100 Plasma
Serum
%
80
60
40
20
0
Sensitivity Specificity PPV NPV T vs. cfDNA
concordance
Figure 3. Comparison of parameters determining KRAS mutation detec-
tion utility between cfDNA plasma and serum samples (M+ Confidence 
Level 3). 
Abbreviations: NPV, negative predictive value; PPV, positive predictive 
value; T, tumour.
the stringency of analysis criteria was reduced from 
those recommended in the kit (ie, 1% ∆Ct and diag-
nostic Ct # 40).22 This effect was most marked for 
plasma-extracted cfDNA samples (Table 4). If it is 
only possible to perform KRAS mutation analysis in 
singleton, the kit guidelines should be used to ensure 
detection of false positives is avoided.
Preferred medium for KRAS mutation 
detection
Plasma- versus serum-extracted cfDNA
To determine which cfDNA sample type was the pre-
ferred medium for KRAS mutation detection, assay 
data for plasma- and serum-extracted cfDNA were 
compared at M+ Confidence Level 3. At this level, 
plasma-extracted  cfDNA  samples  had  marginally 
higher sensitivity (31% vs. 25%) but similar specific-
ity (97% vs. 100%) compared with serum-extracted 
cfDNA samples (Fig. 3). No meaningful differences 
were observed between sample types in NPV or the 
proportion of concordance (the rate at which cfDNA 
and tumor sample results were in agreement) (Fig. 3). 
Overall,  more  KRAS  mutations  were  detected  in 
  plasma-extracted  samples  (10  mutations)  than  in 
those  from  serum  (8  mutations).  Seven  mutations 
were detected in both plasma- and serum-extracted 
cfDNA samples.
Discussion
This study demonstrates that a commercially avail-
able QIAGEN® therascreen KRAS PCR kit can be 
used for the identification of KRAS mutation posi-
tive CRC from plasma and serum samples. It also 
shows that modified analysis criteria can be used to 
increase assay sensitivity without reducing   specificity. 
Analysis success rates for plasma-and serum-  extracted 
cfDNA samples were high (.94%) and mutations in 
KRAS were detected in both sample types. The data 
also suggest that extracting cfDNA from plasma is 
associated with a marginal improvement in assay sen-
sitivity compared with cfDNA from serum.
The KRAS PCR kit had high specificity when used 
with cfDNA (.97% at M+ Confidence Levels 1–3), 
which is consistent with other studies in CRC that 
have  compared  KRAS  testing  results  from  cfDNA 
with those from tumor samples.23,24 By adjusting the 
recommended  analysis  criteria  of  the  PCR  assay, 
we  were  able  to  increase  the  sensitivity  for  detec-
tion of KRAS mutations in the plasma- and serum-
extracted  cfDNA  samples.  Nevertheless,  we  found 
that   sensitivity in both sample types was lower than 
  expected.25 One reason for this might be the limited 
sample   volume (1 mL), which had to suffice for test-
ing in six different assays plus confirmatory analysis. 
Larger volumes of plasma/serum, which could feasibly 
be obtained in a diagnostic setting, might be needed 
to further increase assay sensitivity. Importantly, the 
plasma and serum samples analyzed in this study were 
derived from patients whose tumors had been resected 
at a time point ranging from a few months to 11 years 
prior to the study, and who had previously received 
first-line  anti-cancer  therapy.  Despite  this,  KRAS 
mutations were still detected in the cfDNA of some 
patients. It is therefore possible to speculate that in a Circulating free DNA for KRAS mutation assessment
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diagnostic   setting prior to tumor resection the ability 
to detect KRAS mutations in cfDNA might be further 
enhanced.
A  marked  increase  in  assay  sensitivity  was 
observed  among  serum-extracted  but  not  plasma-
  extracted cfDNA samples when analysis criteria were 
reduced from M+ Confidence Level 1 to Level 2. 
This might be explained by a lower mutation load in 
serum samples. Serum-derived cfDNA can be con-
taminated  with  wild-type  DNA  from  white  blood 
cells, due to lysis of these cells during the sample 
collection.
Repeat analysis of one plasma-extracted cfDNA 
sample  demonstrated  a  reproducible  KRAS M + 
result when no mutation was detected in the FFPE 
tumor sample. Due to insufficient amounts of cfDNA 
it was not possible to verify the additional positive 
result with alternative methods; the tumor DNA was 
sequenced and no evidence of mutation was found. 
This additional positive plasma result might reflect 
tumor heterogeneity. Another possibility is that the 
detected mutation occurred later in disease progres-
sion, after the tumor sample was taken as a biopsy 
sample for diagnosis. Furthermore, it should be taken 
into account that patients received first-line therapy for 
CRC according to their local standard of care before 
serum and plasma samples were collected, though the 
impact of chemotherapy or radiation on the KRAS 
mutation status in CRC is still unclear.2 In addition, 
testing of cfDNA is theoretically representative of all 
tumor sites and may capture mutations occurring at 
sites other than the primary tumor cfDNA. Indeed, 
discordance in the KRAS mutation status of primary 
and  metastatic  tumors  has  previously  been  shown 
to occur in CRC patients, including an example of a 
wild-type primary tumor with a KRAS mutation in the 
metastasis.26
In  summary,  the  higher  specificity  observed  in 
plasma-extracted  compared  with  serum-extracted 
cfDNA samples suggested that future mutation anal-
yses  might  be  preferentially  conducted  in  plasma 
  samples. In addition, based on sensitivity and speci-
ficity data of the plasma- and serum-derived cfDNA 
samples,  we  believe  that  future  mutation  analysis 
based on M+ Confidence Level 3 criteria might be 
appropriate. However, for singleton analysis (if insuf-
ficient cfDNA is available for re-analysis) assay kit 
guidelines and criteria for identifying M+ samples 
should be adhered to in order to avoid the detection 
of false positive results.
It is also important to note that, although high 
PPV gives confidence in predicting positive results, 
low NPV indicates that many mutations are missed 
in cfDNA samples. Therefore, analysis of the KRAS 
mutation  status  in  serum-  or  plasma-extracted 
cfDNA cannot be used for the selection of KRAS 
mutation negative mCRC and a more sensitive assay 
is needed to accurately identify patients with wild-
type KRAS mCRC.
In  conclusion,  this  exploratory  study  with 
matched  tumor,  serum,  and  plasma  samples  from 
patients with mCRC demonstrated that a commer-
cially available assay kit intended for use on FFPE 
CRC tissue can be used to detect KRAS mutations in 
plasma- or serum-extracted cfDNA. For the cfDNA 
samples, assay sensitivity was increased by modifi-
cation of existing assay kit guidelines. Further veri-
fication of the revised analysis criteria is required, 
but the initial results presented here indicate that 
cfDNA may be an important source of tumor DNA 
in a diagnostic setting, especially if access to archi-
val tumor specimens is limited. In addition, the use 
of cfDNA may avoid some of the inherent technical 
challenges associated with DNA analysis of FFPE 
tumor samples.
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